In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Selepressin | Synthetic fragment Nangibotide | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic fragment | |
| Area | Immune and antimicrobial | Immune and antimicrobial | |
| Evidence | |||
| Amount of evidence | 63 | 140 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 17 (3 in people) | 18 (17 in people) | |
| Status | |||
| Approval | Not recorded | Not recorded | |
| Sport (WADA) | |||
| Registered trials | 3 | 1 · 1 active | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Selepressin | Nangibotide |
|---|---|---|
| Adverse eventsWhole body | 532 | 99 |
| Blood pressureCardiovascular |
PepBank is a research reference. Talk to a doctor before you use any peptide.
15591
33 |
| Receptor activity and mechanismRespiratory | 725 | 231157 |
|---|
| MortalityWhole body | 11 | 862 |
|---|
| Inflammation markersImmune and inflammation | 44 | 22211 |
|---|
| Heart functionCardiovascular | 88 | 1515 |
|---|
| Vascular functionRespiratory | 1495 | 651 |
|---|
| Lung injury and fibrosisRespiratory | 44 | 66 |
|---|
| Respiratory functionRespiratory | 11 | 11 |
|---|
| Kidney functionKidney and urinary | 11 | 11 |
|---|
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | Selepressin | Nangibotide |
|---|---|---|
| Blood pressureCardiovascularCompared as: value in the arm that got the peptide, in % | ≈ 50% Patients maintaining MAP >60 mmHg without norepinephrine · selepressin 2.5 ng/kg/minute at 12 h Dose studied: 2.5 ng/kg/minuteUntil shock resolution or a maximum of 7 daysn = 402017 | No randomized trial result 3 results from other study designs. |
| MortalityWhole bodyCompared as: difference from placebo, in % | No randomized trial result 1 result from other study designs. | 12.1% Adjusted absolute mortality improvement Dose studied: 1.0 mg/kg/hn = 2192023 |
≈ 50%
Patients maintaining MAP >60 mmHg without norepinephrine · selepressin 2.5 ng/kg/minute at 12 h
Dose studied: 2.5 ng/kg/minuteUntil shock resolution or a maximum of 7 daysn = 402017
No randomized trial result
3 results from other study designs.
No randomized trial result
1 result from other study designs.
12.1%
Adjusted absolute mortality improvement
Dose studied: 1.0 mg/kg/hn = 2192023
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
3 trials · 2 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Ferring Pharmaceuticals868 participantsJul 2015 to 26 Feb 2018
Septic Shock
Ferring Pharmaceuticals53 participantsNov 2009 to Sept 2011
Septic Shock
Ferring Pharmaceuticals31 participantsJun 2012 to Nov 2013
Septic Shock
1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)
Inotrem355 participants13 Nov 2019 to est. 9 May 2023
Shock, Septic